Why choose Olink for targeted protein biomarker discovery?
Olink has developed a very innovative technology that has a simplicity approach to be able to measure large numbers of proteins. That’s a significant breakthrough for investigators to break into a field of diseases that you could not explore without this technology.Professor C.Thomas Caskey, Baylor College of Medicine, Houston TX.
I am very pleased with the Olink methodology, which has revealed several new biomarkers in the CSF and plasma from patients with multiple sclerosis. It was of particular interest to be able to detect markers in plasma that reflect neuronal damage, including neurofilament light chainsProfessor Tomas Olsson, Center for Molecular Medicine, Karolinska Hospital, Stockholm.
We are impressed by the quality of data delivered by the Olink technology with very small sample sizes. The application in the field of precision medicine is extremely promising.Professor Mathias Uhlen, Science for Life Laboratory & Royal Institute of Technology (KTH), Stockholm
Olink’s immunoassay panels are very useful tools for targeting and discovering protein dynamics in our longitudinal studies, such as the integrative personal omics profile (iPOP)Professor Mike Snyder, Department of Genetics, Stanford University
The Olink panel provided some directions we wouldn’t have considered previously, and is a very appealing strategy for neuroscience projects hoping to identify novel CSF biomarkersTom Lanz, Principal Scientist, Pfizer Neuroscience
In profiling the immune systems of newborn children, the Olink panels allow us to maximize the amount of information extracted from a few microliters of plasma.Assistant Professor Petter Brodin, Department of Medicine, Karolinska Institute, Stockholm.
News & Events Highlights
Olink Proteomics wins major award from Frost & Sullivan
Frost & Sullivan has recognized Olink with the 2018 Global Enabling Technology Leadership Award for the development of our multiplex cardiovascular disease (CVD) panels. Each year, Frost & Sullivan presents this award to a company that develops a pioneering technology that not only enhances current products but also enables new products and application development. We are delighted to get this award, which reflects the impact of the Olink® CVD II and Olink® CVD III panels on clinical research within the cardiovascular field.
View the video and get a flavor of the major international meeting, “Precision Proteomics to Drive Personalized Medicine“, which Olink arranged at the Nobel Forum in Stockholm on June 19, 2018. This global event brought together leading scientists from both academia and industry to listen to a series of outstanding presentations and to engage in important discussions around the increasing importance of protein biomarkers for the development of more personalized healthcare.